SIO announces first grants in interventional oncology /immuno-oncology research programme

124

The Society of Interventional Oncology (SIO and BTG have announced their 2017 Interventional interventional oncology /immuno-oncology research grant recipients.

The interventional oncology /immuno-oncology research programme was established earlier this year to fund initiatives that evaluate how interventional oncology therapies stimulate the immune system; combine locoregional and immunotherapy approaches to improve clinical outcome; and improve the understanding of the underlying mechanisms that cause different therapies to influence adaptive and innate immunity, as well as underlying inflammation and tumorigenesis.

The investigators and project proposals that have been awarded grants are:

  • Rafael Duran, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland, to investigate the immunobiology of hepatocellular carcinoma in patients undergoing Y-90 radioembolization.
  • Joseph P Erinjeri, Memorial Sloan Kettering Cancer Center, New York, USA, for T-Cell clonality and cancer neoantigen presentation following interventional oncology (IO) therapies: which IO techniques optimally stimulate the immune system?
  • Florian J Fintelmann, Massachusetts General Hospital, Boston, USA, for a pilot study of cryoablation combined with immune checkpoint inhibitor therapy in patients with PD-1 refractory metastatic melanoma: prospective clinical research and correlative laboratory studies.
  • Stephen Hunt, University of Pennsylvania, Philadelphia, USA for TAEVax: immunobiologic treatment effects of embolization in a rat hepatocellular carcinoma model.

“We are very pleased that through the generosity of BTG, SIO has been able to fund the most meritorious, cutting-edge research that combines the strengths of interventional oncology and immuno-oncology—two disciplines that hold great promise for improving cancer therapy. The large number of high quality submissions to this grant call attests to the intense interest of interventional oncologists worldwide to continue to advance our field through robust scientific inquiry and clinical study,” stated S Nahum Goldberg, SIO Interventional/Immuno-oncology Working Group chair, and vice-chair for Research and head of the Interventional Oncology Unit, Hadassah Hebrew University Medical Center in Jerusalem, Israel.

Grant recipients were chosen by the SIO Interventional Oncology Immuno-Oncology Working Group, which includes both interventional radiologists and immuno-oncologists. The group plans to publish a white paper later this year to guide further research and clinical practice.

LEAVE A REPLY